Advertisement
EW vs ISRG
Which Stock Would AI Choose? Edwards Lifesciences (EW) vs. Intuitive Surgical (ISRG) Stock Comparison
Key Takeaways
- EW trades at a lower price-to-earnings (P/E) ratio of approximately 44 compared to ISRG's 59, offering relative value in the medtech sector.
- ISRG boasts a significantly larger market capitalization of about $165 billion versus EW's $46 billion, reflecting broader market dominance in robotics.
- Both stocks await first-quarter 2026 earnings, with ISRG showing stronger year-to-date gains around 18% compared to EW's more modest performance.
- Analyst price targets suggest greater upside potential for ISRG at roughly 28% versus EW's 18%.
- Recent weeks have seen mild pullbacks for both amid sector scrutiny, but ISRG benefits from procedure growth momentum.
Introduction
Edwards Lifesciences (EW) and Intuitive Surgical (ISRG) represent leading players in the medical technology sector, focusing on innovative devices for structural heart procedures and robotic-assisted surgery, respectively. This comparison is particularly relevant for growth-oriented investors and traders navigating the medtech landscape, where advancements in minimally invasive treatments drive performance. Amid recent market volatility and upcoming earnings, evaluating their relative valuation, momentum, and catalysts provides insights into potential positioning in portfolios seeking exposure to healthcare innovation.
EW Overview and Recent Performance
Edwards Lifesciences Corporation (EW) is a global leader in patient-focused innovations for structural heart disease, particularly through its transcatheter aortic valve replacement (TAVR) systems and surgical valve technologies. The company reported solid fourth-quarter 2025 results, with revenue of $1.57 billion, though earnings per share (EPS) slightly missed expectations at $0.58. In recent market activity, EW stock has traded within a 52-week range of $68.63 to $87.89, reflecting stability but limited upside amid broader sector pressures. Sentiment has been influenced by anticipation for first-quarter 2026 earnings on April 23, with expected revenue of $1.59 billion and EPS of $0.72, alongside analyst targets averaging $96. Valuation concerns, highlighted by a P/E ratio around 44, have tempered enthusiasm despite growth in procedural volumes.
ISRG Overview and Recent Performance
Intuitive Surgical, Inc. (ISRG) pioneers robotic-assisted minimally invasive surgery via its da Vinci systems, enabling procedures across multiple specialties. Fourth-quarter 2025 results exceeded forecasts, with EPS of $2.53 and revenue of $2.87 billion, driven by 19% procedure growth. Recently, ISRG shares have fluctuated in a 52-week range of $427.84 to $603.88, with year-to-date gains near 18% but a pullback in recent weeks ahead of first-quarter 2026 earnings. Regulatory scrutiny on product safety and CMS payment rules has weighed on sentiment, prompting some analyst target reductions, though averages remain at $591 with strong procedural tailwinds from da Vinci 5 expansions.
Trending AI Robots
Tickeron's Trending AI Robots page showcases 25 top-performing AI trading bots curated from over 350 available on the platform, which collectively trade thousands of tickers across stocks, ETFs, and crypto. These bots employ diverse strategies like swing trading, trend following, and multi-agent approaches on timeframes from 5 minutes to 60 minutes, delivering impressive stats such as annualized returns of 15% to 168%, win rates of 54% to 88%, and profit factors up to 11.7. While none currently feature EW or ISRG in the trending lineup, the section highlights bots excelling in current conditions with risk-managed signals for copy trading. Traders can explore these high performers to align with market dynamics.
Head-to-Head Comparison
EW specializes in niche structural heart solutions, contrasting ISRG's broader robotic platform spanning urology, gynecology, and general surgery. Growth drivers differ: EW relies on TAVR adoption amid aging populations, while ISRG benefits from recurring procedure revenue and system placements. Recent momentum favors ISRG with superior year-to-date returns, though both face earnings volatility. Risk factors include regulatory hurdles for ISRG and competition in valves for EW; EW offers lower valuation and beta near 1 for stability, versus ISRG's premium pricing tied to market leadership. Sector exposure aligns in medtech, but sentiment tilts toward ISRG's scale.
Tickeron AI Verdict
Tickeron's AI models currently lean toward ISRG due to its consistent procedure growth trends, higher analyst upside potential, and dominant positioning in robotic surgery amid expanding total addressable markets. While EW provides attractive valuation, ISRG's stability and catalysts like da Vinci advancements suggest stronger relative momentum in the near term, though both warrant monitoring post-earnings.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is EW is a StrongBuy and ISRG is a Hold.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
EW’s FA Score shows that 1 FA rating(s) are green whileISRG’s FA Score has 0 green FA rating(s).
- EW’s FA Score: 1 green, 4 red.
- ISRG’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
EW’s TA Score shows that 6 TA indicator(s) are bullish while ISRG’s TA Score has 4 bullish TA indicator(s).
- EW’s TA Score: 6 bullish, 4 bearish.
- ISRG’s TA Score: 4 bullish, 4 bearish.
Price Growth
EW (@Medical/Nursing Services) experienced а -1.84% price change this week, while ISRG (@Pharmaceuticals: Other) price change was -3.33% for the same time period.
The average weekly price growth across all stocks in the @Medical/Nursing Services industry was -0.52%. For the same industry, the average monthly price growth was -4.27%, and the average quarterly price growth was -16.56%.
The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was -2.32%. For the same industry, the average monthly price growth was -1.03%, and the average quarterly price growth was -14.58%.
Reported Earning Dates
EW is expected to report earnings on Jul 23, 2026.
ISRG is expected to report earnings on Jul 16, 2026.
Industries' Descriptions
@Medical/Nursing Services (-0.52% weekly)The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.
@Pharmaceuticals: Other (-2.32% weekly)Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.
| EW | ISRG | EW / ISRG | |
| Capitalization | 50.1B | 143B | 35% |
| EBITDA | 1.56B | 3.95B | 39% |
| Gain YTD | 1.994 | -28.812 | -7% |
| P/E Ratio | 46.42 | 48.96 | 95% |
| Revenue | 6.3B | 10.6B | 59% |
| Total Cash | 3.67B | 4.52B | 81% |
| Total Debt | 703M | 87M | 808% |
EW | ISRG | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 66 | 15 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 81 Overvalued | 78 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 66 | |
SMR RATING 1..100 | 69 | 51 | |
PRICE GROWTH RATING 1..100 | 51 | 64 | |
P/E GROWTH RATING 1..100 | 20 | 84 | |
SEASONALITY SCORE 1..100 | 49 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
ISRG's Valuation (78) in the Medical Specialties industry is in the same range as EW (81). This means that ISRG’s stock grew similarly to EW’s over the last 12 months.
ISRG's Profit vs Risk Rating (66) in the Medical Specialties industry is somewhat better than the same rating for EW (100). This means that ISRG’s stock grew somewhat faster than EW’s over the last 12 months.
ISRG's SMR Rating (51) in the Medical Specialties industry is in the same range as EW (69). This means that ISRG’s stock grew similarly to EW’s over the last 12 months.
EW's Price Growth Rating (51) in the Medical Specialties industry is in the same range as ISRG (64). This means that EW’s stock grew similarly to ISRG’s over the last 12 months.
EW's P/E Growth Rating (20) in the Medical Specialties industry is somewhat better than the same rating for ISRG (84). This means that EW’s stock grew somewhat faster than ISRG’s over the last 12 months.
| EW | ISRG | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 68% | 1 day ago 61% |
| Stochastic ODDS (%) | 1 day ago 75% | 1 day ago 57% |
| Momentum ODDS (%) | 1 day ago 64% | 1 day ago 60% |
| MACD ODDS (%) | 1 day ago 60% | 1 day ago 74% |
| TrendWeek ODDS (%) | 1 day ago 60% | 1 day ago 63% |
| TrendMonth ODDS (%) | 1 day ago 55% | 1 day ago 69% |
| Advances ODDS (%) | 8 days ago 59% | 8 days ago 67% |
| Declines ODDS (%) | 12 days ago 59% | 22 days ago 59% |
| BollingerBands ODDS (%) | 1 day ago 62% | 1 day ago 74% |
| Aroon ODDS (%) | 1 day ago 47% | 1 day ago 68% |
Advertisement
EW and
Correlation & Price change
A.I.dvisor indicates that over the last year, EW has been loosely correlated with ISRG. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if EW jumps, then ISRG could also see price increases.